Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m²

Am J Hematol. 2020 Feb;95(2):E51-E54. doi: 10.1002/ajh.25695. Epub 2019 Dec 22.

Authors

Kevin Barley¹, Larysa Sanchez¹, Hearn J Cho¹, Samir Parekh¹, Deepu Madduri¹, Joshua Richter¹, Luis Isola², Talia Goldstein¹, Amishi Dhadwal¹, Katarzyna Zarychta¹, Gillian Morgan Sanchez¹, Donna Catamero¹, Daniel Verina¹, Erika Florendo¹, Moon-Hee Yum¹, Lisa La¹, Jude Gullie¹, Elaine Chan¹, Sundar Jagannath¹, Ajai Chari¹

Affiliations

¹ Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
² Bone Marrow and Stem Cell Transplant Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

PMID: 31814152
DOI: 10.1002/ajh.25695

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Disease-Free Survival
Female
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality*
Oligopeptides / administration & dosage*
Oligopeptides / adverse effects
Survival Rate

Substances

Oligopeptides
carfilzomib

Grants and funding

Amgen/International